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at 5°C and 25°C
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Abstract
Study objectives: To investigate the long-term physical and chemical stability of 0.3 mg/mL and 0.7 mg/mL infusions of 
docetaxel (Teva) in polyolefin bags containing either 0.9% sodium chloride or 5% glucose, stored under refrigerated (2°C–8°C) 
and room temperature (25°C) conditions protected from the light.
Methods: The infusions were prepared aseptically and stored at the two temperatures for 56 days. At various time points, 
chemical stability was determined using a validated stability-indicating, high performance liquid chromatography (HPLC) assay. 
Physical stability was ascertained in terms of visual appearance, pH, weight change of infusions, and sub-visible particles 
counts.
Results: Irrespective of drug concentration, diluent type, or storage temperature, docetaxel infusions were compliant with both 
physical and chemical acceptance criteria over the 56-day study period.
Conclusion: This study has demonstrated the extended stability of docetaxel (Teva) infusions over the concentration range 
0.3–0.7 mg/mL in polyolefin bags containing either 0.9% sodium chloride or 5% glucose and stored at either 2°C–8°C or 
25°C. These findings will enable pre-preparation and storage of these infusions by Centralised Intravenous Additive Services 
(CIVAS) units and the application of dose-banding schemes. As with all infusions where physical stability is potentially limited, 
docetaxel infusions should be carefully inspected for precipitation both before and during use irrespective of the storage period 
before use.
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Introduction
Docetaxel is an anticancer agent 
belonging to the taxane group. It is semi-
synthesised from a substance extracted 
from the needles of the European 
yew tree, Taxus baccata. Docetaxel is 
licensed for use in the EU as mono- or 
combination therapy against cancer of 
the breast, lung, prostate, head and neck, 
and stomach [1].
Docetaxel (Teva) is supplied as an 80 mg 
concentrate containing polysorbate 
80 and absolute ethanol co-solvents, 
and a separate solvent vial of water for 
injection. Once mixed, a solution of 
10 mg/mL is produced and this is further 
diluted in 5% glucose or 0.9% sodium 
chloride to a maximum concentra-
tion of 0.74 mg/mL. According to the 
manufacturer, these infusions should 
be used within four hours at room tem-
perature (< 25°C) [1]. There is a lack 
of data relating to long-term stability of 
docetaxel infusions that would support 
advanced preparation by pharmacy 
Centralised Intravenous Additive 
Services (CIVAS) units or would enable 
inclusion of this drug in dose-banding 
schemes [3, 4]. Dose-banding requires 
extended stability as infusions or pre-
filled syringes are prepared in advance, 
often in a CIVAS unit, and then held in 
the oncology clinic until use [3, 4].
The aim of the study was to investigate 
the extended physical and chemical 
stability of docetaxel over the 
concentration range 0.3–0.7 mg/mL in 
5% glucose and 0.9% sodium chloride 
infusions under refrigerated (5°C ± 3°C) 
and ambient (25°C ± 1°C) storage condi-
tions over 56 days. Docetaxel is almost 
insoluble in water and is formulated with 
ethanol and polysorbate 80 co-solvents 
to facilitate dissolution. Infusions of 
docetaxel are effectively supersaturated 
micellar solutions, and as such are likely 
to exhibit physical instability over time. 
Assessment of physical stability was 
considered to be crucial in this study and 
this was monitored by visual inspection 
and by measuring pH, weight change, 
and sub-visible particle counts. Chemical 
stability was measured using a validated, 
stability-indicating high performance 
liquid chromatography (HPLC) assay.
Materials and methods
Materials
Vials containing docetaxel concentrate 
28 mg/mL, (batch number 7221209, 
expiry 06/2011) and vials containing 
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docetaxel solvent (batch number 
7221209) were supplied by Teva 
Pharmaceuticals, Leeds, UK. The 250 mL 
polyolefin (Viaflo®) infusion bags, con-
taining 0.9% sodium chloride (batch 
number 10E11E2H, expiry 04/2013) and 
5% glucose (batch number 10E05E7M, 
expiry 04/2013) were supplied by Baxter 
Healthcare, Newbury, UK. All pharma-
ceuticals were used within their expiry 
date. All other reagents and chemicals 
were of analytical or HPLC grade (Fisher 
Scientific, Loughborough, UK).
Methods
Preparation of docetaxel infusions
All docetaxel infusions were prepared 
according to the principles of Good 
Pharmaceutical Manufacturing Practice in 
a Class II safety cabinet under ‘Grade A’ 
aseptic conditions. Docetaxel infusions, at 
nominal concentrations of 0.3 mg/mL and 
0.7 mg/mL, were prepared in 0.9% sodium 
chloride and 5% glucose in polyolefin 
bags. Prior to the addition of the docetaxel 
solution a volume of diluent equal to the 
volume of drug solution to be added was 
first withdrawn from the bags. After addi-
tion of docetaxel solution, the bags were 
gently inverted to ensure mixing.
Six infusions of each concentration and 
diluent combination were stored in blue 
polythene overwraps to protect from light 
and placed at either 5°C ± 3°C in a LEC 
pharmaceutical grade refrigerator or at 
25°C ± 1°C in a Gallenkamp incubator. 
The infusion bags were removed at 
specified time points and brought to room 
temperature prior to sampling and analy-
sis. Samples were withdrawn 
under aseptic conditions 
and analysed for physical 
stability in duplicate (colour 
and clarity, weight loss, 
sub-visible particle counts, 
and pH) and chemical 
stability in triplicate using 
a stability-indicating HPLC 
assay. The remaining infu-
sion of each concentration/
diluents combination was 
held as a spare. All infusion 
bags, including those desig-
nated for chemical analysis 
or as spares, were visually 
inspected for clarity and 
colour.
Samples were analysed immediately after 
preparation (t = 0) and at the following 
scheduled time intervals: t = 7, 14, 28, 
42, 56 days.
Chromatographic conditions
Docetaxel concentrations were deter-
mined using a stability-indicating 
reverse-phase HPLC method. The sys-
tem comprised a model PU-2089 Plus 
pump, a model AS-2057 Plus auto-
sampler with in-line degasser, a model 
CO-2060 Plus column oven, a model 
MD-2010 Plus diode array detector, and 
ChromPass (version1.7403.1) software 
(all from Jasco Ltd, Essex, UK). Mobile 
phase comprised 52% acetonitrile: 40% 
sodium acetate buffer pH 5.0. Docetaxel 
separation and quantitative analysis 
were achieved on a Waters Spherisorb® 
ODS2 5 µm column (2.1 mm x 150 mm, 
serial number 0161373341) (Waters 
Ltd, Hertfordshire, UK) with a flow rate 
of 0.3 mL/min and a 227 nm detection 
wavelength. The acquisition run-time 
was seven minutes for each injection. 
Samples were diluted in distilled water 
and injected in duplicate ‘bracketed’ by 
an injection of a freshly-prepared stand-
ard (0.1 mg/mL) stored at 2°C–8°C.
HPLC method validation
Linearity of response
Duplicate injections of seven concentra-
tions over the range 20–160 µg/mL were 
subjected to the HPLC assay described 
above. Mean peak height data were fitted 
by least squares regression to give the 
equation y = 0.004 x -0.005, r2 = 0.994.
Intra-day precision
Replicate samples (n = 5) of docetaxel 
0.1 mg/mL were injected on the same 
day using the above assay. The RSD was 
0.70%.
Inter-day precision
Replicate samples (n = 5) of docetaxel 
0.1 mg/mL were injected on five con-
secutive days using the above assay. The 
RSD was 1.24%.
Stability indication
Docetaxel solution (1 mg/mL) was sub-
jected to treatment with either 0.1 M HCl, 
0.1 M NaOH, 3% H2O2, and heat (all at 
50°C for 30 minutes) and then analysed 
using the above HPLC method. Results 
are presented in Table 1. No docetaxel 
peak was seen in the solution subjected 
to alkaline hydrolysis, either under the 
above conditions or in repeated experi-
ments using milder conditions (ambient 
temperature for 10 minutes). Peak purity 
of the docetaxel peak was > 0.9 in each 
case. In all cases, no additional peaks 
were present and no interference of the 
analyte peak was apparent. It was con-
cluded that the assay was responsive to 
docetaxel degradation and was suitable 
for the purposes of this study.
Column performance and peak symmetry 
were assessed throughout the study 
using the 2011 British Pharmacopoeial 
methods [2].Tailing factor ranged from 
1.311–1.483 whilst the number of 
theoretical plates was typically > 2000. 
This level of performance was consid-
ered acceptable for this study.
Table 1: Stability-indicating ability of the HPLC assay for docetaxel























50°C for 30 min* 1 mL 0.1 
HCl
N/A 0 0
Oxidation 1 mL 
3% H202





50°C for 30 min None 4.634 103.55 0
*No docetaxel was recovered when the alkaline hydrolysis at ambient temperature was repeated with a treatment time 
of only 10 minutes.
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Table 2:  Physicochemical stability of docetaxel (Teva) 0.3 mg/mL and 0.7 mg/mL in 0.9% sodium 
chloride and 5% glucose at 5°C ± 3°C 
Concentration/diluent 











(% initial concentration 
remaining (% RSD))b
10 µm 25 µm
0.3 mg/mL in 0.9% sodium chloride
0 4.48 - 85.70 1.90 Pass 100% = 0.295 mg/mL (2.52)
7 4.48 -0.005 100.90 1.50 Pass 101.43 (1.39)
14 4.43  0.113 97.50 0.80 Pass 100.86 (0.99)
28 4.46 -0.020 177.00 29.50 Pass 102.10 (0.17)
42 4.47 -0.021 123.85 2.30 Pass 100.06 (1.31)
56 4.44  0.022 131.00 5.35 Pass 102.88 (1.25)
0.3 mg/mL in 5% glucose
0 4.16 - 101.30 0.90 Pass 100% = 0.292 mg/mL (2.49)
7 4.17 -0.007 93.70 0.70 Pass 101.52 (0.57)
14 4.12 0.093 106.00 4.65 Pass 100.66 (0.42)
28 4.13 -0.019 104.00 10.00 Pass 100.99 (0.32)
42 4.15 0.000 113.50 18.50 Pass 100.96 (0.13)
56 4.15 0.021  96.30 12.00 Pass 102.47 (0.66)
0.7 mg/mL in 0.9% sodium chloride
0 4.19 - 299.40 8.70 Pass 100% = 0.689 mg/mL (2.10)
7 4.21 -0.009 238.80 1.40 Pass 100.33 (3.19)
14 4.20  0.114 258.35 2.65 Pass 101.41 (3.29)
28 4.18  0.000 427.20 58.15 Pass 100.75 (2.42)
42 4.20 -0.020 263.70 7.80 Pass 101.86 (3.21)
56 4.18  0.021 270.70 11.70 Pass 102.15 (2.56)
0.7 mg/mL in 5% glucose
0 4.03 - 213.70  4.50 Pass 100% = 0.698 mg/mL (0.51)
7 4.03 -0.005 173.90 2.40 Pass 97.82 (2.63)
14 4.05  0.056 200.00 3.50 Pass 98.93 (2.79)
28 4.03  0.019 177.15 6.50 Pass 100.39 (1.61)
42 4.04  0.000 169.00 10.00 Pass 99.06 (2.59)
56 4.03  0.041 153.50 15.50 Pass 100.95 (2.77)
amean of duplicate infusions; bmean of triplicate infusions.
pH measurement
A combination pH electrode and a 
multi-parameter Orion 5-Star pH meter 
(Fisher Scientific, Loughborough, UK) 
calibrated with standard pH 4.0 and 7.0 
reference solutions prior to sample meas-
urement was used to measure the pH of 
duplicate infusions from which the mean 
was recorded.
Weight change
Infusion bags were weighed before and 
after sampling on an electronic precision 
balance (model SG-601, Fisher Scientific, 
Loughborough, UK, resolution 0.01 g). 
Percent weight decrease or increase was 
expressed as the mean of two identical 
infusion bags.
Visual inspection
Infusions were visually 
inspected under standard 
laboratory lighting against 
dark and light backgrounds 
for changes in clarity, colour, 
and presence of particulate 
matter.
Sub-visible particle counts
Counts of 10 µm and 
25 µm diameter particles 
were performed on 3 x 
1 mL infusion samples on 
a LiQuilaz LS200 Particle 
Counter (Particle Measuring 
Technique GB Ltd, Malvern, 
UK). Average cumulative 
counts of duplicate infu-
sions were recorded. The 
instrument was calibrated 
externally.
Acceptance criteria
Stability of infusions at a 
given sampling point was 
confirmed if the following 
conditions were met:
docetaxel assay: 95–105% 
with respect to initial drug 
concentration
pH: change is < 0.5 pH units 
with respect to initial pH
weight change: < 0.2% w/w
appearance: infusions remain 
clear and colourless
sub-visual particles: measured 
for comparative use and to 
support visual observations.
Results
Data for the physical stability (mean of 
duplicate infusions) and chemical stability 
(mean of triplicate infusions) of docetaxel 
over a period of 56 days under refrigerated 
and ambient temperatures are presented in 
Tables 2 and 3 respectively.
At 2°C–8°C all infusions were physically 
stable over 56 days, see Table 2. There 
was no change in visual appearance and 
only very small changes in pH ( 0.05 
pH units). Sub-visible particle counts 
were variable throughout the study and 
the small increases observed did not 
point to impending visual precipita-
tion. Docetaxel concentrations remained 
within 95–105% of the initial (t = 0) con-
centration. Additional peaks were not 
seen in any chromatogram from test sam-
ples. Changes in infusion weights were 
minimal, which excluded the possibility 
that drug degradation could be masked 
by moisture loss from the infusions.
Docetaxel infusions stored at 25°C ± 
1°C, see Table 3, also showed only 
minimal changes in pH over the study 
duration (< 0.15 pH units) whilst 
sub-visible particle counts were again 
variable. In two infusions used for 
physical testing, visible particles were 
seen floating at t = 14 but were not seen 
at subsequent time points. These were 
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Table 3:  Physicochemical stability of docetaxel (Teva) 0.3 mg/mL and 0.7 mg/mL in 0.9% sodium chloride 












(% initial concentration 
remaining (% RSD))b10 µm 25 µm
0.3 mg/mL in 0.9% sodium chloride
0 4.44 - 32.15 1.50 Pass  100% = 0.277 mg/mL (0.93)
7 4.46 -0.055 107.15 4.35 Pass  101.27 (1.02)
14 4.43 -0.076 37.15 1.25 Pass*  99.07 (0.98)
28 4.44 -0.118 106.15 17.30 Pass  97.97 (0.77)
42 4.42 -0.062 39.70 3.30 Pass  97.55 (0.22)
56 4.42 -0.191 62.50 5.00 Pass  98.01 (0.51)
0.3 mg/mL in 5% glucose
0 4.11 - 44.50 0.85 Pass  100% = 0.275 mg/mL (0.68)
7 4.13 -0.072 28.00 3.20 Pass  98.70 (0.41)
14 4.08 -0.074 40.85 2.65 Pass  98.92 (0.94)
28 4.14 -0.096 85.50 3.50 Pass  97.38 (0.81)
42 4.09 -0.080 92.70 5.15 Pass  97.42 (0.39)
56 4.02 -0.167 53.50 2.35 Pass  96.78 (0.75)
0.7 mg/mL in 0.9% sodium chloride
0 4.15 - 45.50 1.30 Pass  100% = 0.644 mg/mL (1.45)
7 4.14 -0.074 96.00 1.50 Pass  101.97 (1.69)
14 4.14 -0.095 47.65 2.80 Pass  98.41 (0.52)
28 4.15 -0.098 66.50 12.35 Pass  99.24 (1.31)
42 4.16 -0.102 93.70 10.80 Pass  98.52 (1.20)
56 4.07 -0.170 61.85 4.50 Pass  98.27 (0.55)
0.7 mg/mL in 5% glucose
0 4.02 - 96.00 3.00 Pass  100% = 0.634 mg/mL (1.57)
7 3.98 -0.054 77.85 4.65 Pass  101.03 (0.17)
14 4.01 -0.261 72.65 3.65 Pass*  99.16 (0.91)
28 4.00 -0.116 69.00 1.85 Pass  98.23 (0.76)
42 3.93 -0.081 121.70 6.70 Pass  97.68 (0.68)
56 3.85 -0.168 93.70 3.65 Pass  98.34 (1.30)
*In both cases the particles seen in the physical testing bags were ‘floating’. The solutions were otherwise clear, colourless, 
and free from haze; amean of duplicate infusions; bmean of triplicate infusions.
attributed to small fragments from the 
addition port septum of the infusion 
bags. All infusions were chemically 
stable with docetaxel concentrations 
remaining within ± 5% of the t = 0 con-
centration. Infusion weight changes 
were small except for a single, isolated 
decrease of 0.261% between day 7 and 
14 of the 0.7 mg/mL in 5% glucose infu-
sion at room temperature.
Discussion
Prolonged stability of docetaxel infusions 
of varying concentrations would enable 
an extended shelf life to be assigned to 
pre-prepared infusions. This would then 
allow inclusion in dose-banding schemes. 
These schemes allow prospective, rather 
than retrospective, microbiological and 
chemical quality control testing and 
therefore enhanced safety, a reduction in 
patient waiting times since the chemo-
therapy is prepared in advance, and 
decreased drug wastage in the case of 
therapy deferral [3, 4]. The platinum-
based drug carboplatin has recently been 
subjected to similar extended stability 
studies [5] and, as a result, clinically 
relevant dose-banding 
regimens have been pro-
posed [6].
Only one infusion failed 
to comply fully with the 
acceptance criteria for 
physical stability. The 
mean decrease (-0.261%) 
in weight of the room 
temperature 0.7 mg/mL 
in 5% glucose infusion at 
day 14, see Table 2, was 
attributed to the weight 
change of a single bag. 
The second bag of the 
infusion pair showed 
almost zero weight 
change. No other weight 
changes for this bag were 
outside the acceptance 
criteria at subsequent 
sampling times and it was 
concluded that this sample 
reading was an artefact. 
Potential explanations 
could be related to the 
presence of condensate 
on the bag surface when 
the initial weight was 
recorded, or to operator 
error. Careful inspection 
of the infusion did not 
identify any leaks.
The few particles seen 
in the two infusion bags 
stored at ambient tem-
perature at day 14 were 
described as ‘floating’ 
particles, see Table 3, and 
did not resemble drug 
precipitate. The solutions 
were otherwise clear and 
colourless. It is likely the particles were 
fragments of the septum cored out dur-
ing repeated sampling. They were not 
seen at later time points and an expla-
nation for this could be that they were 
removed during the subsequent sample 
extraction. It was concluded that this was 
neither microbiological growth nor drug 
precipitation and as a result both bags 
were allowed to remain in the study.
Except for the occasions mentioned above 
the acceptance criteria for chemical and 
physical stability of all infusions were 
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met at all sample points throughout 
the study. These findings are in agree-
ment with those found by Thiesen and 
Krämer [7], who assigned a 28-day shelf 
life to docetaxel infusion.
Sub-visible particle counts were meas-
ured for comparative use and to support 
visual observations. It was thought that 
increased counts might be predictive 
of imminent precipitation, particularly 
in the case of particles > 25 μm diam-
eter. Measuring this parameter is par-
ticularly useful for infusions prepared 
in semi-opaque polyolefin bags, as in 
this case. Throughout the 56 days of the 
study, the counts exhibited small fluc-
tuations, but no obvious trends emerged. 
In contrast, measuring this parameter in 
studies on paclitaxel infusions provided 
some degree of predictive capacity [8].
Many of the counts exceed the Brit-
ish Pharmacopoeial limits of  25/
mL for 10 µm and  3/mL for 25 µm 
for infusions with a volume of more 
than 100 mL [9].In the experience of 
the authors, virtually all cytotoxic infu-
sions prepared by pharmacy CIVAS 
units exceed pharmacopoeial limits for 
sub-visual particles, although in practice 
these are rarely measured.
Under the acidic conditions of the 
infusions (pH 3.93–4.48), docetaxel 
demonstrated chemical stability in 
polyolefin bags. All infusions remained 
within 95–105% of the initial concentra-
tion. This is in accordance with results 
from a 28-day room temperature study 
by Thiesen and Krämer [7]. Unlike 
infusions of the related drug paclitaxel, 
storage temperature had no affect on 
stability. Donyai and Sewell [8] found 
significant precipitation and concomi-
tant decreases in paclitaxel concentration 
occurred more frequently at ambient, 
rather than refrigerated, temperatures. 
Although docetaxel precipitation was 
not observed in this study, we recognise 
that the number of infusions included 
in this study (six infusions for each 
concentration/diluent/temperature com-
bination) was, of necessity, limited. 
It is also accepted that various factors 
can influence the tendency of infusions 
of this type to crystallise, resulting in 
significant variation between infusion 
bags [10]. Such factors can include the 
method of preparation, consistency of 
storage temperature, and the sub-visual 
particulate-load of diluent infusions. 
For these reasons, we strongly advise 
pharmacy and nursing staff to follow the 
precautions described below.
Conclusion
The results from this study demon-
strate that polyolefin bags containing 
docetaxel (Teva) infusions over the con-
centration range 0.3–0.7 mg/mL in either 
0.9% sodium chloride or 5% glucose are 
chemically and physically stable for up 
to 56 days when stored at either 2°C–8°C 
or 25°C and protected from light. As a 
consequence, advanced preparation by 
pharmacy CIVAS units and the applica-
tion of dose-banding schemes for this 
drug can be supported.
Microbiological assessment was not 
part of this investigation, but as with all 
pharmacy prepared infusions the abil-
ity of the CIVAS unit to ensure sterility 
during preparation must be thoroughly 
validated and monitored, especially for 
infusions stored at room temperature. 
Accordingly, the authors recommend 
that unless extended storage times 
are essential, a maximum shelf life of 
28 days should be assigned to docetaxel 
infusions. We also strongly advise that 
all infusions are carefully examined for 
visual precipitation prior to use and at 
intervals during infusion. These precau-
tions will be standard practice in many 
institutions. Since Teva-manufactured 
docetaxel was used in this study, the 
results obtained are only valid for infu-
sions prepared using drug from this 
manufacturer.
Acknowledgement
The authors gratefully acknowledge the 
provision of docetaxel infusion for this 
study by Teva UK.
Author
Professor Graham J Sewell, MRPharmS, 
PhD




Peninsula Allied Health Centre
Derriford Road
Plymouth, PL6 8BH, UK
Tel: +44 1752 588817





1. SPC for Docetaxel Teva 80 mg concentrate. 
Available from: http://www.ema.europa.eu. 
[Accessed 2011 January 05].
2. Appendix III. Chromatographic Separation 
Techniques. British Pharmacopoeia. 2011. 
Available from: http://www.pharmacopoeia.
co.uk. [Accessed 2011 January 11].
3. Kaestner S, Sewell G. Pharmacoeconomic 
aspects of dose-banding. Hosp Pharm Eur. 
2006;26:33-4.
4. Kaestner S, Sewell G. Dose-banding 
of cancer chemotherapy. Hosp Pharm 
Eur.2010;51:31-2.
5. Kaestner S, Sewell G. A sequential 
temperature cycling study for the investi-
gation of carboplatin infusion stability to 
facilitate ‘dose-banding’. J Oncol Pharm 
Pract. 2007;13(2):119-26.
6. Kaestner S, Sewell G. Dose-banding 
of carboplatin: rationale and proposed 
banding scheme. J Oncol Pharm Pract. 
2007;13(2):109-17.
7. Thiesen J, Krämer I. Physico-chemical 
stability of docetaxel premix solution 
and docetaxel infusions in PVC bags and 
polyolefine containers. Pharm World Sci. 
1999;21(3):137-41.
8. Donyai P, Sewell G. Physical and chemical 
stability of paclitaxel infusions in differ-
ent container types. J Oncol Pharm Pract. 
2006;12(4):211-22.
9. Appendix XIII A. Particulate Contamination: 
Sub-visible Particles. British Pharmaco-
poeia 2011. Available from: http://www.
pharmacopoeia.co.uk. [Accessed 2011 
January 17].
10. Acott SR, Hart M. Physical and chemical 
stability of Taxotere 1-vial 20 mg/1 mL infu-
sion solution following refrigerated storage. 
Eur J Oncol Pharm. 2010;4(3):24-6.
